211 related articles for article (PubMed ID: 17412429)
1. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model.
Quik M; O'Neill M; Perez XA
Trends Pharmacol Sci; 2007 May; 28(5):229-35. PubMed ID: 17412429
[TBL] [Abstract][Full Text] [Related]
2. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
Takeuchi H; Yanagida T; Inden M; Takata K; Kitamura Y; Yamakawa K; Sawada H; Izumi Y; Yamamoto N; Kihara T; Uemura K; Inoue H; Taniguchi T; Akaike A; Takahashi R; Shimohama S
J Neurosci Res; 2009 Feb; 87(2):576-85. PubMed ID: 18803299
[TBL] [Abstract][Full Text] [Related]
3. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
Liu B; Dluzen DE
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
[TBL] [Abstract][Full Text] [Related]
4. Microglial activation is not prevented by tacrolimus but dopamine neuron damage is reduced in a rat model of Parkinson's disease progression.
Wright AK; Miller C; Williams M; Arbuthnott G
Brain Res; 2008 Jun; 1216():78-86. PubMed ID: 18495090
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
Emborg ME
J Neurosci Methods; 2004 Oct; 139(2):121-43. PubMed ID: 15488225
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease.
Zhang D; Anantharam V; Kanthasamy A; Kanthasamy AG
J Pharmacol Exp Ther; 2007 Sep; 322(3):913-22. PubMed ID: 17565007
[TBL] [Abstract][Full Text] [Related]
7. Nicotine and nicotinic receptors; relevance to Parkinson's disease.
Quik M; Kulak JM
Neurotoxicology; 2002 Oct; 23(4-5):581-94. PubMed ID: 12428730
[TBL] [Abstract][Full Text] [Related]
8. Nicotinic receptors as CNS targets for Parkinson's disease.
Quik M; Bordia T; O'Leary K
Biochem Pharmacol; 2007 Oct; 74(8):1224-34. PubMed ID: 17631864
[TBL] [Abstract][Full Text] [Related]
9. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
Verma R; Nehru B
Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
[TBL] [Abstract][Full Text] [Related]
10. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates.
Jakowec MW; Petzinger GM
Comp Med; 2004 Oct; 54(5):497-513. PubMed ID: 15575363
[TBL] [Abstract][Full Text] [Related]
11. Multiple roles for nicotine in Parkinson's disease.
Quik M; Huang LZ; Parameswaran N; Bordia T; Campos C; Perez XA
Biochem Pharmacol; 2009 Oct; 78(7):677-85. PubMed ID: 19433069
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture.
Jeyarasasingam G; Tompkins L; Quik M
Neuroscience; 2002; 109(2):275-85. PubMed ID: 11801364
[TBL] [Abstract][Full Text] [Related]
13. Nicotinic receptor modulation for neuroprotection and enhancement of functional recovery following brain injury or disease.
Pauly JR; Charriez CM; Guseva MV; Scheff SW
Ann N Y Acad Sci; 2004 Dec; 1035():316-34. PubMed ID: 15681815
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action.
Park HJ; Lee PH; Ahn YW; Choi YJ; Lee G; Lee DY; Chung ES; Jin BK
Eur J Neurosci; 2007 Jul; 26(1):79-89. PubMed ID: 17581257
[TBL] [Abstract][Full Text] [Related]
15. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K
Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598
[TBL] [Abstract][Full Text] [Related]
16. Amiloride is neuroprotective in an MPTP model of Parkinson's disease.
Arias RL; Sung ML; Vasylyev D; Zhang MY; Albinson K; Kubek K; Kagan N; Beyer C; Lin Q; Dwyer JM; Zaleska MM; Bowlby MR; Dunlop J; Monaghan M
Neurobiol Dis; 2008 Sep; 31(3):334-41. PubMed ID: 18606547
[TBL] [Abstract][Full Text] [Related]
17. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
19. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo.
Du Y; Li X; Yang D; Zhang X; Chen S; Huang K; Le W
Exp Biol Med (Maywood); 2008 Jul; 233(7):881-90. PubMed ID: 18445767
[TBL] [Abstract][Full Text] [Related]
20. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
van Vliet SA; Blezer EL; Jongsma MJ; Vanwersch RA; Olivier B; Philippens IH
Brain Res; 2008 Jan; 1189():219-28. PubMed ID: 18076869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
